Søgeresultater - L.-E. Rutqvist

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    ADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDY

    ADJUVANT GOSERELIN IN PRE-MENOPAUSAL PATIENTS WITH EARLY BREAST CANCER: RESULTS FROM THE ZIPP STUDY af M. Baum, A. Hackshaw, J. Houghtona, L. E. Rutqvist, T. Fornander, B. Nordenskjold, A. Nicolucci, R. Sainsburya

    Udgivet 2014-09-01

    The Zoladex In Pre-menopausal Patients (ZIPP) study was designed to determine whether addition of goserelin (‘Zoladex’) and/or tamoxifen to adjuvant therapy (radiotherapy and/or chemotherapy), provided benefit to pre- or peri-menopausal women with operable, early breast cancer.

    Få fuldtekst
    Article

    Føj til favoritter
    Saved in:
  2. 2
    ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT

    ENDOCRINE TREATMENT OPTIONS FOR ADVANCED BREAST CANCER — THE ROLE OF FULVESTRANT af J.F.R. Robertson, S.E. Come, S.E. Jones, L. Beex, M. Kaufmann, A. Makris, J.W.R. Nortier, K. Possinger, L.-E. Rutqvist

    Udgivet 2014-09-01

    For many years, tamoxifen has been the _gold standard_ amongst anti-oestrogen therapies for breast cancer. However, the selective aro- matase inhibitors (AIs), anastrozole, letrozole and exemestane, have demonstrated advantages over tamoxifen as first-line treatments for advanced disease. Anastrozol...

    Fuld beskrivelse

    Få fuldtekst
    Article

    Føj til favoritter
    Saved in:

Søgeredskaber: